Imperial College
3 inventions
IHC
IF
IP
WB
Antigen/Gene or Protein Targets: Integrin a2bß3 (CD41 & CD61)
0
reviews
4
references
1
supplier
10 reagents managed
Anti-AP2 (a&b) [A6/2/2]
Invented by Helen Hurst at Queen Mary University of London
ELISA
FACS
IHC
IF
RIA
WB
Antigen/Gene or Protein Targets: Activating Protein 2 (AP-2) alpha and beta forms.
0
reviews
6
references
1
supplier
Anti-ErbB4 [HFR1]
Invented by Bill Gullick at Imperial Cancer Research Fund
FACS
IHC
IF
IP
WB
Antigen/Gene or Protein Targets: ErbB4 (Her4, p180erbB4)
0
reviews
10
references
1
supplier
Anti-AP2a [AP2a 8G8/5]
Invented by Helen Hurst at Queen Mary University of London
ChIP
IHC
WB
Antigen/Gene or Protein Targets: Activating Protein 2 (AP-2) alpha (Human)
0
reviews
5
references
1
supplier
Anti-AP2g [AP2g 6E4/4]
Invented by Helen Hurst at Queen Mary University of London
IHC
IP
WB
Antigen/Gene or Protein Targets: Activating Protein 2 (AP-2) gamma
0
reviews
4
references
1
supplier
Anti-AP2b [AP2bß 1F3/8]
Invented by Helen Hurst at Queen Mary Innovation Ltd
ELISA
IHC
WB
Antigen/Gene or Protein Targets: Activating Protein 2 (AP-2) beta
0
reviews
3
references
1
supplier
Anti-AP2b [AP2bß 1G6/2]
Invented by Helen Hurst at Queen Mary University of London
ELISA
IP
WB
Antigen/Gene or Protein Targets: Activating Protein 2 (AP-2) beta (Human)
0
reviews
Add a reference
1
supplier
Anti-SV40ST [pab 280]
Invented by David Lane at University of Dundee
IHC
IF
IP
WB
Antigen/Gene or Protein Targets: SV40 small T antigen
0
reviews
6
references
1
supplier
Anti-RIP140 [6D7]
Invented by Bill Gullick at Imperial Cancer Research Fund
![Western blotting on an array of lysates prepared from cultured cells using anti-RIP140 [6D7]. Antibody dilution: 1/500, incubated o/n in PBS+NaN3. Secondary: anti-mouse HRP, 1/2000, 1h. Exposure: 1min](https://res.cloudinary.com/ximbio/image/upload/c_thumb,fl_lossy,h_124,q_auto,r_max,w_124/f1234c16-ce81-4f83-97be-1233395de777.jpg)
